Breastfeeding - Revision history

Frances.Sarkari@anthonynolan.org: /* Justification for Guidance */

2025-06-25T12:49:23Z

Justification for Guidance

Frances.Sarkari@anthonynolan.org: /* Date of Last Update */

2025-06-25T12:47:36Z

Date of Last Update

Frances.Sarkari@anthonynolan.org: /* Justification for Guidance */

2025-06-25T12:46:56Z

Justification for Guidance

Frances.Sarkari@anthonynolan.org at 16:59, 16 January 2024

2024-01-16T16:59:30Z

Frances.Sarkari@anthonynolan.org: Blanked the page

2023-11-30T11:53:20Z

Blanked the page

PaulM at 15:17, 25 April 2018

2018-04-25T15:17:38Z

PaulM: Created page with "==Acceptability at Recruitment== ACCEPTABLE, but should be deferred for 6 months after labour. ==Acceptability at CT / Work-Up== QUALIFIED, see below ==Individual at Risk==..."

2018-04-25T15:17:16Z

Created page with "==Acceptability at Recruitment== ACCEPTABLE, but should be deferred for 6 months after labour. ==Acceptability at CT / Work-Up== QUALIFIED, see below ==Individual at Risk==..."

New page

==Acceptability at Recruitment==
ACCEPTABLE, but should be deferred for 6 months after labour.

==Acceptability at CT / Work-Up==
QUALIFIED, see below

==Individual at Risk==
Donor

==Guidance==

For Bone Marrow - donors willing to donate BM and who wish to resume breastfeeding post donation, should wait for at least 24 hours after the last dose of anaesthetic was administered, to avoid transfer it to the baby (general anaesthesia may cause severe events in the baby).

For PBSC - donors willing to donate PBSC should stop breastfeeding prior to the first dose of G-CSF and resume it at least 48 hours after the last dose has been administered, also to avoid contact of the baby with G-CSF. The safety profile of G-CSF has not been tested during pregnancy thus the it is unknown whether baby is at risk of adverse events.

==Pseudonyms or Related Conditions==

← Older revision		Revision as of 12:49, 25 June 2025
Line 34:		Line 34:
	'''Donor Lymphocyte Collection'''		'''Donor Lymphocyte Collection'''

−	Donors ~~can~~ continue ~~to breastfeed~~ up until the time of donation. ~~The donor~~ should ~~withhold breastfeeding~~ during the donation and ~~on the journey~~ home ~~then~~ can ~~resume breastfeeding~~ once home.	+	Donors may continue breastfeeding up until the time of donation. Breastfeeding should be paused during the donation itself and while travelling home. It can be safely resumed once the donor has returned home.

← Older revision		Revision as of 12:47, 25 June 2025
Line 66:		Line 66:

	====Date of Last Update====		====Date of Last Update====
−	29/11/~~2023~~	+	25/06/2025

← Older revision		Revision as of 12:46, 25 June 2025
Line 30:		Line 30:

	Anaesthetic drugs are generally very short-lived in the maternal blood stream. Breast-feeding may continue up until anaesthetic induction prior to the bone marrow harvest, and mothers may recommence feeding 24 hours following recovery from anaesthetic, i.e after 'waking up'. If any other medications are given around the time of the procedure, such as sedating benzodiazepines (e.g. midazolam/diazepam), or opiates (e.g. morphine/codeine) then advice should be sought from the attending anaesthetist.		Anaesthetic drugs are generally very short-lived in the maternal blood stream. Breast-feeding may continue up until anaesthetic induction prior to the bone marrow harvest, and mothers may recommence feeding 24 hours following recovery from anaesthetic, i.e after 'waking up'. If any other medications are given around the time of the procedure, such as sedating benzodiazepines (e.g. midazolam/diazepam), or opiates (e.g. morphine/codeine) then advice should be sought from the attending anaesthetist.
		+
		+
		+	'''Donor Lymphocyte Collection'''
		+
		+	Donors can continue to breastfeed up until the time of donation. The donor should withhold breastfeeding during the donation and on the journey home then can resume breastfeeding once home.

← Older revision	Revision as of 16:59, 16 January 2024
Line 1:	Line 1:
	+	==Acceptability at Recruitment==
	+	ACCEPTABLE

	+	==Acceptability at CT / Work-Up==
	+	QUALIFIED if the donor is sufficiently informed about and accepts the fact that there are limited data on safety or is willing to interrupt breastfeeding (and throw away any expressed milk, “pump and dump”) during mobilization and for three days after PBSC and for at least 24 hours after Bone Marrow Collection (discuss case per case with the attending anesthesiologist).
	+
	+	==Individual at Risk==
	+	Donor
	+
	+	==Explanation of Condition==
	+
	+
	+	==Justification for Guidance==
	+
	+	We generally recommend that breast-feeding mothers do not donate and, regardless of breast-feeding, donation is not permitted within six months of a term pregnancy.
	+
	+	However, many breast-feeding donors who are more than six months following delivery feel very strongly that they would like to donate, and would be prepared to stop or suspend breast-feeding at the time of donation.
	+
	+
	+	'''PBSC harvest'''
	+
	+	Breast-feeding donors may donate by PBSC if they are prepared to stop breast-feeding on commencing G-CSF injections and to abstain for three days following their donation. It is safe for the mother to express before this three-day period has expired, but the expressed milk should be discarded.
	+
	+	In donors who breastfeed and are qualified to donate (taking the recovery period after pregnancy into consideration) the concern is that drugs used in the donation procedure may be ingested by and harmful for the infant. In line with this, several donor suitability guidance documents consider uninterruptible breastfeeding a contra-indication for PBSC and ask the donor if she is willing to interrupt breastfeeding during mobilization and for a couple of days after donation.
	+	However, G-CSF is a normal component of breast milk. Limited research shows that filgrastim and lenograstim are poorly excreted into breastmilk and are undetectable by 3 days after an injection. Evidence also suggests that G-CSF given to neonates orally is not absorbed in significant quantities. In a single-center crossover study in which 22 infants received 1 dose of rhG-CSF (100 microg/kg) (10 times the subcutaneous dose) orally, no side-effects, safety issues or significant changes in plasma G-CSF concentration were observed. In a placebo controlled study G-CSF was safely given to 8 infants suffering from necrotizing enterocolitis. These studies suggest that G-CSF mainly has a local effect on the GI tract and not systemically.
	+
	+
	+
	+	'''Bone marrow harvest'''
	+
	+	Anaesthetic drugs are generally very short-lived in the maternal blood stream. Breast-feeding may continue up until anaesthetic induction prior to the bone marrow harvest, and mothers may recommence feeding 24 hours following recovery from anaesthetic, i.e after 'waking up'. If any other medications are given around the time of the procedure, such as sedating benzodiazepines (e.g. midazolam/diazepam), or opiates (e.g. morphine/codeine) then advice should be sought from the attending anaesthetist.
	+
	+
	+	See also
	+
	+	[[Pregnancy]]
	+
	+	==Pseudonyms or Related Conditions==
	+	Breastfeeding
	+
	+	==References==
	+
	+	1.Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? Hum Reprod Update. 2013;19:259–67. [PubMed]
	+
	+	2.Shibata H, Yamane T, Aoyama Y, et al. Excretion of granulocyte colony-stimulating factor into human breast milk. Acta Haematol. 2003;110:200–1. [PubMed]
	+
	+	3.Nelson RC. Granulocyte colony-stimulating factor (G-CSF) in breastmilk of a nursing donor during hematopoietic progenitor cells (HPC) mobilization. Transfusion 2018;58 (Suppl S2):169A. Abstract. doi:10.1111/trf.14903. [CrossRef]
	+
	+	4.Kaida K, Ikegame K, Fujioka T, et al. Kinetics of granulocyte colony-stimulating factor in the human milk of a nursing donor receiving treatment for mobilization of the peripheral blood stem cells. Acta Haematol. 2007;118:176–7. [PubMed]
	+
	+	5.Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. Pediatrics. 2003;112:421–3. [PubMed]
	+
	+	6.Canpolat FE, Yurdakok M, Korkmaz A, et al. Enteral granulocyte colony-stimulating factor for the treatment of mild (stage I) necrotizing enterocolitis: a placebo-controlled pilot study. J Pediatr Surg. 2006;41:1134–8. [PubMed]
	+
	+	7.Drugs and Lactation Database (LactMed). https://www.ncbi.nlm.nih.gov/books/NBK501373/
	+
	+	8. Specialist Pharmacy Service. https://www.sps.nhs.uk/medicines/filgrastim/#:~:text=filgrastim
	+
	+	==Version==
	+	Version 2, Edition 1
	+
	+	====Date of Last Update====
	+	29/11/2023

← Older revision		Revision as of 11:53, 30 November 2023
Line 1:		Line 1:
−	~~==Acceptability at Recruitment==~~
−	~~ACCEPTABLE, but should be deferred for 6 months after labour.~~

−	~~==Acceptability at CT / Work-Up==~~
−	~~QUALIFIED, see below~~
−
−	~~==Individual at Risk==~~
−	~~Donor~~
−
−	~~==Guidance==~~
−
−	For Bone Marrow - donors willing to donate BM and who wish to resume breastfeeding post donation, should wait for at least 24 hours after the last dose of anaesthetic was administered, to avoid transfer it to the baby (general anaesthesia may cause severe events in the baby).
−
−
−	For PBSC - donors willing to donate PBSC should stop breastfeeding prior to the first dose of G-CSF and resume it at least 48 hours after the last dose has been administered, also to avoid contact of the baby with G-CSF. The safety profile of G-CSF has not been tested during pregnancy thus the it is unknown whether baby is at risk of adverse events.
−
−	~~==Pseudonyms or Related Conditions==~~

@@ Line 11: / Line 11: @@
 For Bone Marrow - donors willing to donate BM and who wish to resume breastfeeding post donation, should wait for at least 24 hours after the last dose of anaesthetic was administered, to avoid transfer it to the baby (general anaesthesia may cause severe events in the baby).
 For PBSC - donors willing to donate PBSC should stop breastfeeding prior to the first dose of G-CSF and resume it at least 48 hours after the last dose has been administered, also to avoid contact of the baby with G-CSF. The safety profile of G-CSF has not been tested during pregnancy thus the it is unknown whether baby is at risk of adverse events.
 ==Pseudonyms or Related Conditions==